Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval dosing (EID), who switched to ocrelizumab and to c...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, María Ezquerra-Marigomez, Marta Torres-Barquin, Cristina Menéndez-Garcia, Fernando Uriarte, Yésica Jiménez-López, Mercedes Misiego, Jose Ramón Sánchez de la Torre, Sonia Setien, Manuel Delgado-Alvarado, Javier Riancho
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2023-02-01
Sarja:	Frontiers in Immunology
Aiheet:	extended interval dosing natalizumab ocrelizumab multiple sclerosis PML - progressive multifocal leukoencephalopathy
Linkit:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1086028/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!